45 results on '"Ziranu P"'
Search Results
2. 490P New horizons in metastatic colorectal cancer: Role of CD44 expression
3. 467P Monocyte to red blood cells ratio (MRR): an innovative haematologic prognostic parameter in FOLFIRI-aflibercept treated patients: A subgroup analysis from the DISTINCTIVE trial
4. 407P Neoadjuvant chemo-radiotherapy response in patients affected by mismatch repair deficient (dMMR) locally advanced rectal cancer
5. 417P Liquid biopsy driven anti-EGFR rechallenge in metastatic colorectal cancer
6. 459P Dynamic changes of pro-angiogenic factors during FOLFIRI-aflibercept treatment: Interim analysis of DISTINCTIVE trial
7. P-128 Influence of anti-diabetic medications on the outcomes of patients with pancreatic ductal adenocarcinoma and type 2 diabetes mellitus
8. PD-5 Retrospective comparative analysis of K-ras G12C vs other K-ras mutations in metastatic colorectal cancer patients treated with first-line chemotherapy doublet + bevacizumab
9. P-127 Lymphocyte to monocyte ratio as a prognostic factor in stage IV pancreatic ductal adenocarcinoma naive patients before gemcitabine-nab-paclitaxel chemotherapy
10. P-129 Concomitant RAS and BRAF mutations: Impact on overall survival and progression free survival in metastatic colorectal cancer patients
11. 126P From tumor height (TH) to tumor regression grade (TRG) in locally advanced rectal cancers (LARC) during total neadjuvant therapy (TNT): A retrospective analysis
12. 109P Early onset metastatic colorectal cancer: Clinical-prognostic characteristics and correlation to molecular status
13. 349P The influence of diabetes on taxane-induced neurotoxicity and quality of life in breast cancer patients
14. P-298 Adjuvant chemotherapy in resected lung-limited metastatic patients with colorectal cancer
15. P-292 The Meta-Lung score: Preoperative clinical score in lung-limited metastatic patients with colorectal cancer
16. P-166 Influence of levothyroxine concomitant treatment on treatment responses and outcomes in patients with metastatic colorectal adenocarcinoma
17. P-160 Mismatch repair system protein deficiency as a resistance factor for locally advanced rectal adenocarcinoma patients receiving neoadjuvant chemo-radiotherapy
18. 373P The role of concomitant RAS and BRAF mutations in influencing clinical outcome during BRAF-targeted treatment for metastatic colorectal cancer
19. Correlation between p53 expression and clinical outcome in RAS/BRAF wild type metastatic colorectal cancer patients receiving later-line irinotecan-cetuximab
20. Effectiveness of CA 19.9 in predicting prognosis in metastatic pancreatic cancer patients treated with nab-paclitaxel plus gemcitabine
21. A new prognostic score for biliary tract cancer: a multicenter experience
22. Overall survival and progression-free survival in metastatic colorectal cancer patients with concomitant RAS and BRAF mutations: a single center experience
23. The DISTINCTIVE study: A biologically enriched phase II study of seconD-line folfiri/aflIbercept in proSpecTIvely stratified, anti-EGFR resistaNt, metastatic coloreCTal cancer patIents with RAS Validated wild typE status - Trial in progress
24. P 53 abnormal expression might influence global outcome through EGFR modulation in RAS/BRAF wild type metastatic colorectal cancer patients receiving later-line irinotecan cetuximab
25. Medical management of malignant bowel obstruction: our center experience
26. Fentanyl pectin nasal spray for breakthrough cancer pain treatment: a single center experience
27. Management of breakthrough cancer pain in patients with oral mucositis
28. The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild type colorectal cancer patients receiving irinotecan/cetuximab
29. 601P - Correlation between p53 expression and clinical outcome in RAS/BRAF wild type metastatic colorectal cancer patients receiving later-line irinotecan-cetuximab
30. P-332 - A new prognostic score for biliary tract cancer: a multicenter experience
31. P-296 - Overall survival and progression-free survival in metastatic colorectal cancer patients with concomitant RAS and BRAF mutations: a single center experience
32. P-230 - Effectiveness of CA 19.9 in predicting prognosis in metastatic pancreatic cancer patients treated with nab-paclitaxel plus gemcitabine
33. Selection with a molecUlar PanEl foR Panitumumab EfficAcy in K-ras and n-ras wild type metastatic colorectal cancer (SUPER- PEAK)
34. REINVENT (REgorafenIb traNslational eValuation angiogENesis proTocol)
35. Selection with a molecUlar PanEl foR Panitumumab EfficAcy in K-ras and n-ras wild type metastatic colorectal cancer (SUPER- PEAK)
36. REINVENT (REgorafenIb traNslational eValuation angiogENesis proTocol)
37. P-291 - The DISTINCTIVE study: A biologically enriched phase II study of seconD-line folfiri/aflIbercept in proSpecTIvely stratified, anti-EGFR resistaNt, metastatic coloreCTal cancer patIents with RAS Validated wild typE status - Trial in progress
38. P-209 - P 53 abnormal expression might influence global outcome through EGFR modulation in RAS/BRAF wild type metastatic colorectal cancer patients receiving later-line irinotecan cetuximab
39. U10 - Management of breakthrough cancer pain in patients with oral mucositis
40. U3 - Fentanyl pectin nasal spray for breakthrough cancer pain treatment: a single center experience
41. A22 - The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild type colorectal cancer patients receiving irinotecan/cetuximab
42. 606TiP - Selection with a molecUlar PanEl foR Panitumumab EfficAcy in K-ras and n-ras wild type metastatic colorectal cancer (SUPER- PEAK)
43. 603TiP - REINVENT (REgorafenIb traNslational eValuation angiogENesis proTocol)
44. D47 - REINVENT (REgorafenIb traNslational eValuation angiogENesis proTocol)
45. D46 - Selection with a molecUlar PanEl foR Panitumumab EfficAcy in K-ras and n-ras wild type metastatic colorectal cancer (SUPER- PEAK)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.